Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.

@article{Yu2015ClinicalOA,
  title={Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.},
  author={Joanne L. Yu and Kelvin K. W. Chan and Michael Kurin and Mark Pasetka and Alex Kiss and Srikala S. Sridhar and Ellen Warner},
  journal={The breast journal},
  year={2015},
  volume={21 6},
  pages={658-64}
}
Docetaxel and cyclophosphamide (TC) is a widely used breast cancer adjuvant regimen. We sought to compare the rates of febrile neutropenia (FN) between patients receiving no primary prophylaxis (PP) and those receiving PP with either granulocyte-colony stimulating factor (G-CSF) or antibiotics. We also analyzed cost-effectiveness of TC with and without either G-CSF or antibiotics. Charts were reviewed of all 340 patients who received adjuvant TC between January 2008 and December 2012 at two… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Institute for Clinical Research and Health Policy Studies, Tufts Medical Center

  • Center for the Evaluation of Value, MA Risk in Health. The Cost-Effectiveness Analysis Re Boston
  • Available at: www.cearegistry.org
  • 2013

Estimation of the incidence of febrile neutropenia in women receiving docetaxel plus cyclophosphamide as adjuvant therapy for early-stage breast cancer: a large community-based retrospective study

  • RE Bordoni, S Haislip, JW Gilmore, J Sharpe, MR Choi, E. Abella
  • Commun Oncol
  • 2012
2 Excerpts

Similar Papers

Loading similar papers…